Company Information-BioKangtai

Home page

Home page

Company Information

Biominhai Collaborates with Dek Vaccines for 13-Valent PCV Technology Transfer and Drug Supply

02/11 .2025

Biominhai Collaborates with Dek Vaccines for 13-Valent PCV Technology Transfer and Drug Supply

BioKangtai: 20-Valent Pneumococcal Vaccine Enters Phase II Clinical Trial

04/03 .2025

BioKangtai: 20-Valent Pneumococcal Vaccine Enters Phase II Clinical Trial

BioKangtai and AstraZeneca Announce Strategic Partnership to Advance Global Vaccine Innovation

04/03 .2025

BioKangtai and AstraZeneca Announce Strategic Partnership to Advance Global Vaccine Innovation

BioKangtai at VIF: Shaping the Future of Global Vaccine Cooperation

04/03 .2025

BioKangtai at VIF: Shaping the Future of Global Vaccine Cooperation

BioKangtai Reaches Vaccine Technology Transfer Cooperation Intent with Ethiopia

04/03 .2025

BioKangtai Reaches Vaccine Technology Transfer Cooperation Intent with Ethiopia

DCVMN CEO Visits BioMinhai: Paving the Way for Vaccine Collaboration

03/24 .2025

DCVMN CEO Visits BioMinhai: Paving the Way for Vaccine Collaboration

BioKangtai’ s COVID-19 Inactivated Vaccine Received Approval for Clinical Trial

10/27 .2020

BioKangtai’ s COVID-19 Inactivated Vaccine Received Approval for Clinical Trial

BioKangtai’ s COVID-19 Inactivated Vaccine Received Approval for Clinical Trial

< 1 2 3 4 >